Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Karnofsky index \> 60 % (ECOG \< 2)~* Histologically confirmed muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy.~* Pathological T-stage \> pT3, and/or pathological N-stage \> pN1, and/or residual tumor present after surgery (R\>1)~* No distant metastases~* Written informed consent~Exclusion Criteria:~* Prior RT in the pelvic region~* Presence of distant metastases~* Pregnancy~* Inability to consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adiuvant Radiotherapy +/- CT (Type: EXPERIMENTAL): The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~* R0: PTVb + PTVn 50 Gy in 25 fractions~* R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS\<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).